Clinical Trials Logo

Stage I Breast Cancer clinical trials

View clinical trials related to Stage I Breast Cancer.

Filter by:

NCT ID: NCT04578106 Recruiting - Clinical trials for HER2-positive Breast Cancer

Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy

ELPIS
Start date: September 23, 2020
Phase: Phase 2
Study type: Interventional

This is a prospective, single arm, open-label, unicenter, exploratory study in women with primary operable HER2-positive, HER2-enriched/ERBB2-high breast cancer according to PAM50 intrinsic subtype and a ERBB2 pre-defined cutoff (high vs low ERBB2 expression), to evaluate the omission of surgery and sentinel lymph node dissection in patients with HER2-E and ERBB2 high breast cancer who achieving a complete response following standard anti-HER2-based neoadjuvant therapy with paclitaxel/trastuzumab/pertuzumab. The primary trial objective is to estimate the loco-regional invasive disease-free survival at 3-year of patients who achieve a complete response based on imaging (i.e. Magnetic resonance imaging) and a stereotactic-guided vacuum-assisted breast biopsy, and omit loco-regional surgery.

NCT ID: NCT04007770 Active, not recruiting - Gynecologic Cancer Clinical Trials

Acupuncture Pilot Study for Cancer-related Cognitive Function

Start date: July 1, 2019
Phase: Phase 2
Study type: Interventional

This study is being done to explore whether acupuncture can improve cognitive difficulties in patients diagnosed with cancer.

NCT ID: NCT03834532 Completed - Clinical trials for Breast Cancer Female

Living Well After Breast Surgery

Start date: February 18, 2019
Phase: N/A
Study type: Interventional

Decision making about whether to have breast reconstruction after mastectomy can be difficult, and previous studies have found that many women are not well informed about their options. Patient decision aids can improve decision quality for a variety of health conditions. This pilot randomized study seeks to determine how a patient decision aid about breast reconstruction affects the quality of decisions about reconstruction including patient knowledge, concordance between preferences and treatment, and decisional regret.

NCT ID: NCT03691311 Active, not recruiting - Clinical trials for Stage II Breast Cancer

Biomarker Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast Cancer

D-BIOMARK
Start date: July 5, 2018
Phase: Early Phase 1
Study type: Interventional

This is a biomarker study designed to test the preclinically generated hypothesis of anti-tumoral activity of denosumab in patients with early breast cancer candidates a tumour excision

NCT ID: NCT03345420 Active, not recruiting - Clinical trials for Stage II Breast Cancer

Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer

NOVEMBER
Start date: December 12, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well hypofractionated radiation therapy works in treating patients with stage 0-IIB breast cancer. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects.

NCT ID: NCT03284346 Terminated - Obesity Clinical Trials

Exercise in Targeting Metabolic Dysregulation in Stage I-III Breast or Prostate Cancer Survivors

Start date: August 17, 2017
Phase: N/A
Study type: Interventional

This randomized pilot clinical trial studies how well circuit, interval-based aerobic and resistance exercise works in targeting metabolic dysregulation in stage I-III breast or prostate cancer survivors. Circuit, interval-based aerobic and resistance exercise may help to improve cardiovascular fitness, weight loss, healthy lifestyle behaviors, and muscle strength in breast or prostate cancer survivors.

NCT ID: NCT03233555 Completed - Clinical trials for Stage II Breast Cancer

Extended Cancer Education for Longer-Term Survivors in Primary Care for Patients With Stage I-II Breast or Prostate Cancer or Stage I-III Colorectal Cancer

Start date: September 3, 2013
Phase: N/A
Study type: Interventional

This study tests four different methods of educating patients about follow-up care (NCI facing forward, brochure, EXCELS website alone, EXCELS health coaching alone and EXCELS website & health coaching combination) after cancer treatment ends. While it is known that patients need information to guide follow-up it remains unknown how to best provide this in primary care.

NCT ID: NCT03198286 Completed - Clinical trials for Stage IIIA Breast Cancer

Carevive Survivor Care Planning System in Improving Quality of Life in Breast Cancer Survivors

Start date: August 1, 2015
Phase: N/A
Study type: Interventional

This pilot clinical trial studies how well the Carevive Survivor Care Planning System works in improving quality of life in breast cancer survivors. A personalized survivor care plan includes a summary of a patient's cancer treatment and a customized survivor care plan and may provide beneficial information and resources.

NCT ID: NCT03139435 Completed - Clinical trials for Stage IV Breast Cancer

Ultrasound in Detecting Taxane-Induced Neuropathy in Patients With Breast Cancer

Start date: May 11, 2017
Phase: N/A
Study type: Interventional

This pilot clinical trial studies how well ultrasound works in detecting taxane-induced neuropathy in patients with breast cancer. Ultrasound may work better in diagnosing and detecting neuropathy in breast cancer patients treated with the chemotherapy drug called a taxane.

NCT ID: NCT03128619 Terminated - Clinical trials for Stage IV Breast Cancer

Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer

Start date: August 2, 2017
Phase: Phase 1
Study type: Interventional

This phase I/II trial studies side effects and best dose of copanlisib when given together with letrozole and palbociclib and to see how well they work in treating hormone receptor positive HER2 negative stage I-IV breast cancer. Copanlisib and palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs, such as letrozole, may lessen the amount of estrogen made by the body. Giving copanlisib, letrozole, and palbociclib may work better in treating patients with breast cancer.